Bladder cancer-related microbiota: examining differences in urine and tissue samples

Mansour, Bassel; Monyók, Ádám; Makra, Nóra; Gajdács, Márió; Vadnay, István; Ligeti, Balázs; Juhász, János; Szabó, Dóra; Ostorházi, Eszter

doi:10.1038/s41598-020-67443-2

Cited by 78 publications

(105 citation statements)

References 38 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, in HNC studies, microbiome composition, and diversity appeared similar when using saliva, tumor tissue, or tumor swab [ 33 ]. The same has been shown in patients with urothelial cancer when using urine and tumor tissue [ 160 ]. However, more studies to further evaluate this are needed.…”

Section: Microbiome In Oncology: Are We Ready For Prime Time?supporting

confidence: 62%

Tumor-Associated Microbiome: Where Do We Stand?

Oliva

Mulet-Margalef

Olza

et al. 2021

IJMS

View full text Add to dashboard Cite

The study of the human microbiome in oncology is a growing and rapidly evolving field. In the past few years, there has been an exponential increase in the number of studies investigating associations of microbiome and cancer, from oncogenesis and cancer progression to resistance or sensitivity to specific anticancer therapies. The gut microbiome is now known to play a significant role in antitumor immune responses and in predicting the efficacy of immune-checkpoint inhibitors in cancer patients. Beyond the gut, the tumor-associated microbiome—microbe communities located either in the tumor or within its body compartment—seems to interact with the local microenvironment and the tumor immune contexture, ultimately impacting cancer progression and treatment outcome. However, pre-clinical research focusing on causality and mechanistic pathways as well as proof-of-concept studies are still needed to fully understand the potential clinical utility of microbiome in cancer patients. Moreover, there is a need for the standardization of methodology and the implementation of quality control across microbiome studies to allow for a better interpretation and greater comparability of the results reported between them. This review summarizes the accumulating evidence in the field and discusses the current and upcoming challenges of microbiome studies.

show abstract

Section: Microbiome In Oncology: Are We Ready For Prime Time?supporting

confidence: 62%

Tumor-Associated Microbiome: Where Do We Stand?

Oliva

Mulet-Margalef

Olza

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…In fact, a recent study compared the urinary microbiota from catheterized-urine samples with the bladder mucosa-associated microbiota using tissue samples in patients suffering bladder cancer. Important differences in some taxa were found in this study, which suggest that the bladder tissue microbiota and the urinary microbiota might differ to some extent ( Mansour et al., 2020 ).…”

Section: Urinary Microbiome or Urobiomementioning

confidence: 83%

Urinary Microbiome: Yin and Yang of the Urinary Tract

Pérez-Carrasco

Soriano‐Lerma

Soriano

et al. 2021

Front. Cell. Infect. Microbiol.

121

132

View full text Add to dashboard Cite

The application of next generation sequencing techniques has allowed the characterization of the urinary tract microbiome and has led to the rejection of the pre-established concept of sterility in the urinary bladder. Not only have microbial communities in the urinary tract been implicated in the maintenance of health but alterations in their composition have also been associated with different urinary pathologies, such as urinary tract infections (UTI). Therefore, the study of the urinary microbiome in healthy individuals, as well as its involvement in disease through the proliferation of opportunistic pathogens, could open a potential field of study, leading to new insights into prevention, diagnosis and treatment strategies for urinary pathologies. In this review we present an overview of the current state of knowledge about the urinary microbiome in health and disease, as well as its involvement in the development of new therapeutic strategies.

show abstract

“…They also found Klebsiella was more common in the urine of female patients versus healthy controls. Of note is that Klebsiella have been linked with bladder cancer in another study (Mansour et al, 2020). It is postulated that the Klebsiella could cause direct DNA-strand damage and generate genomic instability by releasing colibactin toxin (Kaur et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study

Zeng

Zhang

Chen

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Numerous studies indicate that resident microbiome exists in urine of healthy individuals and dysbiosis of the urobiome (urinary microbiome) may be associated with pathological conditions. This study was performed to characterize the alterations in urobiome and explore its implications of clinical outcome in male patients with bladder cancer. 62 male patients with bladder cancer and 19 non-neoplastic controls were recruited. The follow-up study cohort included 40 patients who were diagnosed with non-muscle invasive bladder cancer (NMIBC) and underwent transurethral resection of bladder tumor (TURBT). Mid-stream urine samples were collected from all the participants the day before cystoscopy. DNA was extracted from urine pellet samples and processed for high throughput 16S rRNA amplicon sequencing of the V4 region using Illumina MiSeq. Sequencing reads were filtered using QIIME and clustered using UPARSE. We found bacterial richness indices (Observed Species index, Chao1 index, Ace index; all P < 0.01) increased in cancer group when compared with non-neoplastic group, while there were no differences in Shannon and Simpson index between two groups. During a median follow-up time of 12 (5.25–25) months, 5/40 (12.5%)of the patients developed recurrence and no patient suffered from progression to muscle-invasive disease. Species diversity of the microbiome was significantly higher in the recurrence group compared with non-recurrence group in patients with NMIBC after TURBT. The LEfSe analysis demonstrated that 9 genera were increased (e.g., Micrococcus and Brachybacterium) in recurrence group. To our knowledge we report the relative comprehensive study to date of the male bladder cancer urinary microbiome and its relationship to pathogenesis and clinical outcomes. Given our preliminary data, additional studies evaluating the urine microbiome in relation to clinical outcomes are warranted to improve our understanding of tumor recurrence after TURBT.

show abstract

Bladder cancer-related microbiota: examining differences in urine and tissue samples

Cited by 78 publications

References 38 publications

Tumor-Associated Microbiome: Where Do We Stand?

Tumor-Associated Microbiome: Where Do We Stand?

Urinary Microbiome: Yin and Yang of the Urinary Tract

Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study

Contact Info

Product

Resources

About